CBC, Total Cholesterol and Triglycerides Test in Delhi

CBC + Total Cholesterol + Triglycerides Test at Home

The CBC + Total Cholesterol + Triglycerides combination panel focuses on the two most commonly elevated and clinically actionable lipid markers alongside a Complete Blood Count. Total cholesterol and triglycerides are the first-line lipid measurements in most screening programmes, initial treatment decisions, and follow-up monitoring where a full multi-fraction lipid profile is not yet indicated or needed.

While a full lipid profile also provides LDL-C and HDL-C as individually calculated fractions, total cholesterol and triglycerides together give clinicians meaningful initial cardiovascular risk information in a more focused, cost-efficient form. They are particularly useful in periodic follow-up monitoring after a baseline full lipid profile has already been established, or as the first screen in a patient where results will determine whether a fuller panel is warranted.

MAX@Home delivers this panel through a single fasting blood draw at your home by a certified phlebotomist. Results from a partner NABL-accredited laboratory reach you as a digital authenticated report within 24 to 48 hours.

What Total Cholesterol Measures

Total cholesterol (TC) is the aggregate of all cholesterol-containing lipoprotein fractions circulating in the blood: LDL-C (the primary atherogenic fraction), HDL-C (the protective fraction), VLDL-C (carrying triglycerides and also atherogenic), and minor intermediate fractions. It is measured as a single value by a direct enzymatic assay that does not require the individual fractions to be separated.

What total cholesterol tells you: and what it doesn't

A total cholesterol above 200 mg/dL in adults is considered borderline high; above 240 mg/dL is high. At the population level, high total cholesterol predicts cardiovascular events. At the individual level, it is a less precise tool than the full lipid fractions because it conflates the harmful (LDL-C, VLDL-C) and protective (HDL-C) components. A patient with TC of 220 mg/dL due predominantly to elevated HDL-C has a far better cardiovascular risk profile than one with the same TC driven by elevated LDL-C and low HDL. This is why an elevated total cholesterol on initial screening generally prompts a full lipid profile to identify the component driving the elevation.

Calculating LDL-C from total cholesterol and triglycerides

When total cholesterol, HDL-C, and triglycerides are measured together (as in a full lipid profile), LDL-C can be calculated using the Friedewald equation: LDL-C = Total cholesterol − HDL-C − (Triglycerides ÷ 5). In this focused panel, HDL-C is not separately measured. However, total cholesterol and triglycerides together still allow VLDL-C to be estimated (approximately Triglycerides ÷ 5), and non-HDL cholesterol can be estimated when combined with a separately available HDL-C value. Many clinicians use this panel as a monitoring checkpoint when baseline full lipid fractions are already on record, using the TC and TG to assess whether overall lipid burden is trending in the right direction.

Factors that affect total cholesterol

• Diet: saturated fat and trans fat raise LDL-C (and therefore TC); omega-3 fatty acids modestly lower it.
• Age: TC tends to rise through middle age in both sexes, then stabilise; post-menopausal women often see a steeper rise as oestrogen-mediated HDL protection diminishes.
• Genetics: Familial hypercholesterolemia produces markedly elevated TC from birth due to LDL receptor dysfunction; it often manifests as TC above 300 mg/dL in adults and above 250 mg/dL in children.
• Medical conditions: hypothyroidism, CKD, and cholestatic liver disease raise TC; hyperthyroidism and liver failure lower it.
• Medications: corticosteroids, oral contraceptives, and immunosuppressants typically raise TC; statins lower it.

What Triglycerides Measure

Triglycerides are the primary storage form of dietary fat and the main energy fuel mobilised from adipose tissue between meals. In the blood, they are transported within VLDL particles produced by the liver and within chylomicrons absorbed from the gut after meals. This is why a fasting sample is essential: non-fasting triglycerides include a variable post-prandial chylomicron peak that makes the result uninterpretable for screening or treatment decisions.

Normal and abnormal triglyceride ranges

• Below 150 mg/dL: normal fasting triglycerides.
• 150 to 199 mg/dL: borderline high, often found in metabolic syndrome; lifestyle modification is the first intervention.
• 200 to 499 mg/dL: high, independently associated with cardiovascular risk and metabolic syndrome; pharmacological treatment may be considered alongside lifestyle change.
• 500 mg/dL and above: very high, risk of acute pancreatitis becomes clinically significant; urgent treatment with fibrates or omega-3 fatty acids is usually indicated.

Why triglycerides rise: the main causes

Most hypertriglyceridaemia in clinical practice is secondary to metabolic causes rather than genetic. Type 2 diabetes and insulin resistance are the most common underlying drivers: high insulin promotes hepatic VLDL synthesis and impairs peripheral triglyceride clearance. Obesity, particularly abdominal obesity, amplifies this effect. Alcohol raises triglycerides by multiple mechanisms: increased hepatic fatty acid synthesis, reduced fatty acid oxidation, and impaired VLDL clearance. Hypothyroidism reduces lipoprotein lipase activity, impairing triglyceride clearance. Certain medications (oral contraceptives, particularly high-oestrogen formulations, corticosteroids, beta-blockers, and antiretrovirals) raise triglycerides through various metabolic mechanisms. Genetic hypertriglyceridaemia, including familial hypertriglyceridaemia and familial combined hyperlipidaemia, accounts for the more refractory cases.

Triglycerides and pancreatitis risk

When triglycerides rise above 500 mg/dL, and particularly above 1000 mg/dL, the risk of acute hypertriglyceridaemia-induced pancreatitis becomes clinically significant. Triglyceride-rich lipoproteins are hydrolysed by pancreatic lipase within the pancreatic microcirculation, releasing free fatty acids that directly damage acinar cells and endothelial surfaces. Hypertriglyceridaemic pancreatitis accounts for approximately five percent of all acute pancreatitis cases in adults. Detecting and treating triglycerides before they reach this threshold is one of the practical reasons for periodic monitoring with this panel.

What the Complete Blood Count Adds

In the context of a cholesterol and triglyceride screen, the CBC contributes several clinically relevant dimensions:

Anaemia detection alongside cardiovascular risk

Unrecognised anaemia in patients with elevated cholesterol and triglycerides is clinically important because anaemia increases cardiac output demand and is an independent predictor of adverse cardiovascular outcomes in high-risk patients. Finding anaemia alongside dyslipidaemia prompts investigation of the anaemia cause - which might be iron deficiency, B12 deficiency, or the normocytic anaemia of metabolic syndrome - and allows both conditions to be addressed simultaneously.

Hypothyroidism suspicion: the link between high TC and anaemia

Hypothyroidism is a common and frequently missed cause of both elevated total cholesterol (through reduced hepatic LDL receptor activity) and normocytic or macrocytic anaemia (through reduced erythropoietin production and B12 absorption). When the CBC shows anaemia alongside elevated total cholesterol or triglycerides without obvious dietary or metabolic cause, hypothyroidism is a high-priority differential, and thyroid function testing (TSH) becomes the natural next investigation.

Polycythaemia and cardiovascular risk

Elevated haemoglobin and haematocrit (polycythaemia) increases blood viscosity and raises the risk of thrombosis, which compounds the cardiovascular risk already present from dyslipidaemia. Secondary polycythaemia from chronic smoking (through elevated carboxyhaemoglobin stimulating erythropoietin) or chronic lung disease is detected on the CBC and adds context to a high total cholesterol reading in the same report. Smoking is simultaneously the major driver of secondary polycythaemia and one of the strongest amplifiers of dyslipidaemia-driven coronary risk.

Conditions This Panel Evaluates

Cardiovascular Disease Risk Screening

Elevated total cholesterol and triglycerides are independent, modifiable risk factors for atherosclerosis, coronary artery disease, stroke, and peripheral arterial disease. Total cholesterol above 240 mg/dL doubles the risk of coronary artery disease compared with TC below 200 mg/dL. High triglycerides compound this risk, particularly when accompanied by low HDL-C (which can be inferred from other clinical indicators even when not measured in this panel). Detecting and treating dyslipidaemia before a first cardiovascular event is the goal of population-level screening.

Metabolic Syndrome

Elevated triglycerides combined with the other metabolic syndrome components (central obesity, elevated fasting glucose, low HDL-C, and hypertension) constitute a cluster of cardiovascular and metabolic risk that the International Diabetes Federation (IDF) and ATP III criteria define as metabolic syndrome. This panel identifies two of the lipid components directly and the haematological context through the CBC. A finding of elevated triglycerides on this panel is a reliable prompt to check for the other metabolic syndrome components.

Hypertriglyceridaemia: Primary and Medication-Induced

Primary genetic hypertriglyceridaemia (familial hypertriglyceridaemia, familial combined hyperlipidaemia) and secondary hypertriglyceridaemia from medications, alcohol, diabetes, or hypothyroidism are all detectable from triglyceride elevation on this panel. The CBC provides contextual clues: macrocytosis may suggest alcohol use or B12 deficiency alongside medication-induced hypertriglyceridaemia; anaemia alongside high triglycerides suggests hypothyroidism or CKD-related dyslipidaemia.

Monitoring Response to Lipid-Lowering Treatment

Patients on statins, fibrates, or omega-3 fatty acid supplements are commonly monitored with total cholesterol and triglycerides between full lipid profile reviews. This panel is appropriate as an interim checkpoint between annual full lipid profile reviews, confirming that TC and triglycerides are trending toward or remaining within treatment targets without the full-panel cost.

Who Should Get This Test

• Adults above 35 for initial cardiovascular risk screening, or from age 25 for those with a family history of early heart disease or genetic lipid disorders.
• Patients with obesity, metabolic syndrome, or type 2 diabetes who need periodic triglyceride and cholesterol monitoring.
• Those on oral contraceptives, corticosteroids, beta-blockers, or antiretrovirals, all of which adversely affect triglycerides.
• Patients on statin therapy being monitored as an interim check between full lipid profile reviews.
• Individuals with a history of pancreatitis or familial hypertriglyceridaemia requiring periodic safety monitoring.
• Patients with known alcohol use disorders where triglycerides and haematological indices (macrocytosis) need periodic review.

How to Prepare for the Test

Fasting is essential

A minimum ten to twelve hour fast is required for this panel. Non-fasting triglycerides include a variable chylomicron contribution from the previous meal that renders the result unreliable for screening and treatment decisions. Total cholesterol is less affected by a recent meal but is also most accurately interpreted in the fasting state. Water may be consumed freely throughout the fast.

Specific instructions before the test

• Avoid alcohol for 48 hours before the test: alcohol can raise triglycerides to two to three times the fasting baseline even with moderate intake.
• Eat a normal dinner the evening before. A very high-fat or very high-carbohydrate meal the night before may still marginally affect next-morning fasting triglycerides.
• Do not stop prescribed medications, including statins, fibrates, or diabetes medications, before the test.
• Avoid intense exercise for 24 hours before the test; exercise affects haematological parameters in the CBC and can transiently alter cholesterol metabolism.

How to Book with MAX@Home

MAX@Home makes fasting morning blood test straightforward from home.

1.  Visit the MAX@Home website or call the helpline and select the CBC + Cholesterol Total + Triglycerides panel.

2.  Schedule a morning appointment, ideally between 7 and 10 a.m., after an overnight fast of at least ten hours.

3.  A certified phlebotomist arrives at your home with all sterile collection equipment.

4.  A single venous blood draw provides the sample for all components of the panel.

5.  Samples are dispatched to a partner NABL-accredited laboratory.

6.  Your digital authenticated report is delivered within 24 to 48 hours.